NCT01582191 2025-10-27
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
Clinical Trials
11 trialsNCT02123823 2025-07-15
BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT01624766 2021-02-25
Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02077933 2020-12-08
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
Novartis
Phase 1 Completed
NCT00955773 2017-11-09
Cancer
GlaxoSmithKline
Phase 1 Completed
NCT01508104 2017-08-23
Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors
University of Cincinnati
Phase 1 Terminated
NCT01642732 2017-05-30
Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 1 Terminated
NCT00985374 2016-11-02
A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Terminated
NCT00187174 2015-03-04
Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
St. Jude Children's Research Hospital
Phase 1 Completed
NCT01096199 2014-01-22
A Study of TS-1, Cisplatin (CDDP) and RAD001 (Everolimus)
National University Hospital, Singapore
Phase 1 Terminated
NCT00496600 2012-06-14
Phase I Study of Patupilone and RAD001
Rutgers, The State University of New Jersey
Phase 1 Completed